Niagen Bioscience, Inc. Common Stock
NAGENiagen Bioscience, Inc. is a biotechnology company focused on developing and commercializing nicotinamide riboside (NR), a form of vitamin B3 that supports cellular health and energy metabolism. The company aims to leverage its proprietary NAD+ booster to address various age-related health conditions and promote overall wellness.
Company News
Niagen Bioscience (NASDAQ: NAGE) reported doubled annual profits and 30% revenue growth for 2025, reaching $129.4 million in net sales. CEO Rob Fried announced the company is actively pursuing acquisitions and expanding into new markets including at-home injection kits and cosmetics partnerships. However, 2026 guidance of $145 million (15% growth...
The National Advertising Division reviewed claims by Reus Research for its Cata-Kor NAD+ products, finding some claims supported while recommending modifications or discontinuation of others due to insufficient substantiation of health benefits and inadequate influencer disclosures.
